MAR 01, 2017 10:30 AM PST

New Molecule Halts Growth of Fatal Pediatric Brain Tumor

WRITTEN BY: Xuan Pham

A sinister brain tumor that claims the lives of every affected child may now be stopped with a new molecule drug.

The brain tumor is known as diffuse intrinsic pontine glioma (DIPG), and it affects about 300 children every year in the US. The tumor is located in the pons of the brain, a part of the brainstem that relays messages from the forebrain to the cerebellum. “This tumor kills every single kid who gets DIPG within one year. No one survives,” said Andrea Piunti, underscoring the extremely aggressive nature of this tumor. Piunti is the study’s first author who is a postdoctoral fellow at the Northwestern University Feinberg School of Medicine.

Previously, the same lab identified a potential pathway mutation behind DIPG. In particular, they published that a mutation in the histone H3 molecule may be driving the growth of DIPG in fruit fly models. In follow-up work, the team demonstrated that a drug that corrected the effects of the mutation was able to prolong survival in mice by 20 days.

Now, the team sought to demonstrate the effects of the drug in DIPG patient-derived tumors in mice when directly injected in the brainstem. The drug is a BET bromodomain inhibitor, which prevent binding of bromodomain proteins to the mutant histone protein. These molecules are already used in a variety of other clinical trials as potential cancer therapies.

The team observed that treatment with the drug halted the tumor growth in mice. Furthermore, the drug triggered differentiation in the tumor cells, which also contributed to the reduction in tumor growth. Mice treated with BET inhibitor had significantly extended survival as compared to untreated mice.

“To the best of our knowledge, this is the most effective molecule so far in treating this tumor,” said Dr. Ali Shilatifard, the study’s senior author. “Every other therapy that has been tried so far has failed.”

Because BET inhibitors are available and have been used to treat leukemia, the researchers hope to apply it to clinical trials for DIPG patients next. Additionally, the team postulated that the BET inhibitor may be combined with other promising DIPG therapies, such as histone deacetylase (HDAC) inhibitors, with positive synergistic effects.

Additional sources: Northwestern University

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
JUL 22, 2021
Cell & Molecular Biology
Cancer Cells in the Lab Aren't Like Cancer Cells in the Body
JUL 22, 2021
Cancer Cells in the Lab Aren't Like Cancer Cells in the Body
To study biology, researchers need models. Once those models might have been a bit limited to organisms like rats or mic ...
AUG 18, 2021
Cell & Molecular Biology
Insight Into an Antiviral Enzyme That Can Impact Cancer Cells
AUG 18, 2021
Insight Into an Antiviral Enzyme That Can Impact Cancer Cells
For many years, researchers have studied how an enzyme called APOBEC3 can help protect the body from pathogenic viruses, ...
AUG 23, 2021
Cancer
A Safe and Effective Combination Therapy for Advanced Cancer
AUG 23, 2021
A Safe and Effective Combination Therapy for Advanced Cancer
Immunotherapies are emerging as a promising strategy for the treatment of late-stage cancers which currently have m ...
AUG 25, 2021
Chemistry & Physics
Self-Assembling Molecules: A Potential "One-Size-Fits-All" Cancer Therapy
AUG 25, 2021
Self-Assembling Molecules: A Potential "One-Size-Fits-All" Cancer Therapy
A new study from the University of Huddersfield shows promising breakthroughs on the use of self-assembling molecules as ...
SEP 23, 2021
Drug Discovery & Development
The FDA approves the first and only oral treatment for a certain non-small cell lung cancer.
SEP 23, 2021
The FDA approves the first and only oral treatment for a certain non-small cell lung cancer.
Last week, the United States Food and Drug Administration (FDA) granted approval for the first oral therapy to ...
OCT 14, 2021
Cancer
Mechanism of Resistance to Colorectal Cancer Treatment Uncovered
OCT 14, 2021
Mechanism of Resistance to Colorectal Cancer Treatment Uncovered
Colorectal cancer develops when a series of changes occur across multiple genes.  While researchers have paid signi ...
Loading Comments...